Compare Krispy Kreme Inc (DNUT) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Krispy Kreme Inc vs TG Therapeutics Inc — how do they compare? Krispy Kreme Inc trades at $2.96 (market cap $521.37M), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 15.7× Krispy Kreme Inc's market cap, and Krispy Kreme Inc pays a 3.47% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Krispy Kreme Inc for 46 Days and TG Therapeutics Inc for 16 Days on average.
| DNUT | TGTX | |
|---|---|---|
Market Cap | $521.37M | $8.16B |
Volume | 2,293,015 | 1,735,121 |
Sector | Consumer Staples | Health |
52-Week High | $4.70 | $59.06 |
52-Week Low | $2.87 | $26.94 |
Typical Hold Time | 46 Days | 16 Days |
Enterprise Value | $1.76B | $8.37B |
Dividend Yield | 3.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Krispy Kreme (DNUT) trades at $3.01, up 3.08% today, showing bullish technical signals despite mixed earnings. The company reported a net loss of $515.77 million in 2025, with negative profit margins, but maintains a strong gross margin of 75.19%. Recent news highlights product launches like the Pokémon doughnut collection but also ongoing legal investigations into fiduciary duties.
The outlook is cautious; while analyst consensus leans buy (50%), fundamental weaknesses in profitability and elevated P/E ratio of 216.5 pose risks. Positive cash flow from operations of $33.92 million in 2025 offers some stability, but investors should weigh legal overhangs against product innovation-driven sentiment.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Krispy Kreme Inc
Krispy Kreme Inc is a sweet treat brands company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in- your-mouth experience. It operates in 30 countries through its network of fresh Doughnut Shops, partnerships with retailers, and a growing ecommerce and delivery business. The company conducts its business through the following three reported segments namely U.S. and Canada, includes all operations in the U.S. and Canada, Insomnia Cookies shops, and the Branded Sweet Treat Line
Read more on DNUT →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
